Design Therapeutics GAAP EPS of -$0.23 beats by $0.02 [Seeking Alpha]
Design Therapeutics, Inc. (DSGN)
Company Research
Source: Seeking Alpha
Cash, cash equivalents and marketable securities were $254.1 million as of September 30, 2024, which the company expects to fund its planned operating expenses into 2029. More on Design Therapeutics Seeking Alpha's Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Design Therapeutics to Participate in Multiple Upcoming Investor ConferencesGlobeNewswire
- Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioGlobeNewswire
- We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
DSGN
Earnings
- 11/7/24 - Beat
DSGN
Sec Filings
- 12/19/24 - Form 4
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- DSGN's page on the SEC website